The Cancéropôle Lyon Auvergne-Rhône-Alpes (CLARA), a cancer research cluster, is an initiative launched and funded by public authorities (French National Cancer Institute, regional authorities and the European Regional Development Fund). It is part of the French National Cancer Plans, and its purpose is to foster cancer research in the Auvergne-Rhône-Alpes region.
Since 2003, CLARA has been bringing together academic, clinical and industry stakeholders from Auvergne-Rhône-Alpes to advance regional, national and international strategies for cancer. Its goal is twofold: rapid transfer of discoveries to patients and the commercial application of research.
It has worked to energize and enrich cancer research by mobilizing the Auvergne-Rhône-Alpes area’s strengths in the field. This organizational effort aims to go beyond institutional, geographical, sectorial and subject-related barriers in order to synergize these strengths so as to more effectively conribute to the fight against cancer.
CLARA is also developing initiatives to broaden cancer research to include the humanities and social sciences as well as public health issues, putting patients at the core of research.
A leader in research and its application to cancer treatment in Auvergne-Rhône-Alpes, CLARA is continuously developing and strengthening its relationships with researchers, clinicians and entrepreneurs as part of an ecosystem of development organizations, incubators and competitive clusters, notably over the last two years with Lyonbiopôle.
Ten years after its creation, CLARA has developed a ground-breaking and now proven model: establishment of high-performance platforms, certifications of projects of scientific excellence (LabEx DEVweCAN, SIRIC LYric, Carnot CALYM Institute, and others), a portfolio of 30 transfer projects with strong potential, five of which are in clinical development, and one applying for marketing authorization, implementation of the Japanese biotech OncoTherapy Science, to name a few.